Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Psoriasis

MalaCards integrated aliases for Psoriasis:

Name: Psoriasis 12 74 52 36 29 54 42 3 15 62 17 71 32


External Ids:

Disease Ontology 12 DOID:8893
KEGG 36 H01656
MeSH 43 D011565
NCIt 49 C3346
SNOMED-CT 67 9014002
ICD10 32 L40 L40.9
UMLS 71 C0033860

Summaries for Psoriasis

KEGG : 36 Psoriasis (PSORS) is a chronic, immune-mediated inflammatory skin disease, characterized by increased propagation of the epidermis with dilation of dermal capillaries. The major symptoms of psoriasis are itchy, scaly, and flaky skin, swelling, pain, and disfiguring skin lesions. Plaque psoriasis is the most common form. Other forms include flexural, guttate, nail, inverse psoriasis, erythroderma, and psoriatic arthritis. Nail psoriasis can accompany any form of psoriasis or occur of its own accord. It can occur in any age group, but psoriatic arthritis usually develops between the ages of 30-50 years. Various factors such as bacterial infection, genetic and environmental factors, and immune disorders play an important role in causing psoriasis. Psoriasis is associated with several comorbidities, including cardiovascular disease, lymphoma, and depression. Psoriasis is an immune-mediated disease with genetic predisposition, but no distinct immunogen has been identified. The presence of cytokines, dendritic cells, and T lymphocytes in psoriatic lesions has prompted the development of biologic therapies. The diagnosis is usually clinical, based on the presence of typical erythematous scaly patches, papules, and plaques that are often pruritic and sometimes painful. Biopsy is rarely needed to confirm the diagnosis. First-line therapies for most patients are topical treatments such as topical corticosteroids and vitamin D analogs. For those with more severe or treatment-resistant disease, second- or third-line therapies include phototherapy, systemic therapies such as methotrexate, and more recently biologic therapies such as tumour necrosis factor (TNF) inhibitors.

MalaCards based summary : Psoriasis is related to psoriasis 7 and psoriasis 10, and has symptoms including pruritus, exanthema and psoriasiform rash. An important gene associated with Psoriasis is MIR203A (MicroRNA 203a), and among its related pathways/superpathways is MicroRNAs in cancer. The drugs Esomeprazole and Dapsone have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and testes.

Disease Ontology : 12 A skin disease that is characterized by patches of thick red skin and silvery scales.

NIH Rare Diseases : 52 Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. The skin on the elbows, knees, scalp, back, face, palms and feet is most often affected, but other parts of the body can be affected as well. A problem with the immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in the skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because the cells rise too fast. Although symptoms may come and go, for many, psoriasis is a lifelong condition. Infections, stress, dry skin and certain medications may make symptoms worse. Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medications and light therapy.

MedlinePlus : 42 Psoriasis is a skin disease that causes itchy or sore patches of thick, red skin with silvery scales. You usually get the patches on your elbows, knees, scalp, back, face, palms and feet, but they can show up on other parts of your body. Some people who have psoriasis also get a form of arthritis called psoriatic arthritis. A problem with your immune system causes psoriasis. In a process called cell turnover, skin cells that grow deep in your skin rise to the surface. Normally, this takes a month. In psoriasis, it happens in just days because your cells rise too fast. Psoriasis can be hard to diagnose because it can look like other skin diseases. Your doctor might need to look at a small skin sample under a microscope. Psoriasis can last a long time, even a lifetime. Symptoms come and go. Things that make them worse include Infections Stress Dry skin Certain medicines Psoriasis usually occurs in adults. It sometimes runs in families. Treatments include creams, medicines, and light therapy. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

CDC : 3 Psoriasis is a chronic autoimmune skin disease that speeds up the growth cycle of skin cells.

PubMed Health : 62 About psoriasis: Psoriasis is a non-contagious inflammatory disease. The main symptoms are reddish, scaly patches of skin that may itch. It is a chronic condition that is typically associated with periods of more severe skin problems (flare-ups) followed by periods of milder skin problems or none at all. Various treatments can relieve the symptoms, but there is no cure for psoriasis. Its severity can vary quite a lot. In some people it is bothersome more than anything else, and they can cope with it quite well. Others feel that it has a major effect on their quality of life, since the treatment and skin care can take a long time. Many people are also unhappy about having visible reddened and scaly skin patches – especially if they are on exposed areas of their body. Sometimes the inflammation that is causing the psoriasis affects other parts of the body too, such as the joints or nails.

Wikipedia : 74 Psoriasis is a long-lasting autoimmune disease characterized by raised areas of abnormal skin. These... more...

Related Diseases for Psoriasis

Diseases in the Psoriasis family:

Psoriasis 1 Psoriasis 3
Psoriasis 2 Psoriasis 4
Psoriasis 5 Psoriasis 6
Psoriasis 7 Psoriasis 9
Psoriasis 8 Psoriasis 10
Psoriasis 11 Psoriasis 12
Psoriasis 13 Psoriasis 15

Diseases related to Psoriasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1285)
# Related Disease Score Top Affiliating Genes
1 psoriasis 7 35.2 PSORS7 PSORS1C3
2 psoriasis 10 35.2 PSORS1C3 PSORS10
3 psoriasis 8 35.2 PSORS8 PSORS1C3
4 psoriasis 5 35.2 PSORS5 PSORS1C3
5 psoriasis 3 35.1 PSORS3 PSORS1C3
6 psoriasis 6 35.1 PSORS6 PSORS1C3
7 psoriasis 9 35.1 PSORS9 PSORS1C3
8 skin disease 32.4 MIR31 MIR21 MIR203A MIR17 MIR146A MIR142
9 non-alcoholic fatty liver disease 31.3 MIR31 MIR21 MIR203A MIR200A MIR17
10 arteries, anomalies of 30.9 MIR21 MIR17 MIR146B MIR146A MIR142
11 bone inflammation disease 30.8 MIR21 MIR17 MIR146A MIR142
12 connective tissue disease 30.6 MIR31 MIR21 MIR17 MIR146B MIR146A MIR142
13 polymyositis 30.5 MIR21 MIR146B
14 lymphoma, non-hodgkin, familial 30.5 MIR31 MIR21 MIR17 MIR146B MIR142
15 spinal disease 30.5 MIR21 MIR17 MIR146A MIR142
16 heart valve disease 30.4 MIR21 MIR17 MIR146A
17 cardiovascular system disease 30.3 MIR21 MIR17 MIR146A MIR142
18 gastrointestinal system disease 30.3 MIR31 MIR21 MIR200A MIR17 MIR146B MIR146A
19 mouth disease 30.3 MIR31 MIR21 MIR17 MIR142
20 rectum cancer 30.2 MIR31 MIR21 MIR200A MIR17
21 oral squamous cell carcinoma 30.2 MIR31 MIR21 MIR203A MIR17 MIR146A
22 leukemia, acute myeloid 30.1 MIR326 MIR31 MIR21 MIR17 MIR146A MIR142
23 leukemia, chronic lymphocytic 30.1 MIR31 MIR21 MIR17 MIR146A MIR142
24 pharynx cancer 30.1 MIR31 MIR21 MIR17 MIR142
25 lung cancer susceptibility 3 30.0 MIR31 MIR21 MIR200A MIR17 MIR146B MIR142
26 thyroid gland disease 30.0 MIR17 MIR146B MIR142
27 renal cell carcinoma, nonpapillary 30.0 MIR31 MIR21 MIR200A MIR17 MIR142
28 immune system disease 30.0 MIR31 MIR21 MIR200A MIR17 MIR146B MIR146A
29 intestinal disease 30.0 MIR31 MIR21 MIR200A MIR17 MIR146B MIR142
30 bladder cancer 29.9 MIR31 MIR21 MIR203A MIR200A MIR17 MIR146A
31 hematologic cancer 29.9 MIR31 MIR21 MIR17 MIR146B MIR146A MIR142
32 digeorge syndrome 29.8 MIR31 MIR200A MIR17 MIR142
33 disease of mental health 29.7 MIR21 MIR17 MIR142
34 psoriasis 14, pustular 13.0
35 psoriasis 1 12.9
36 guttate psoriasis 12.7
37 pustular psoriasis 12.7
38 psoriasis 13 12.7
39 psoriasis 11 12.7
40 psoriasis 2 12.7
41 psoriasis 15, pustular 12.6
42 psoriasis 4 12.6
43 psoriasis 12 12.6
44 psoriatic arthritis 12.5
45 psoriasis 15 12.5
46 pustulosis of palm and sole 12.4
47 mental retardation and psoriasis 12.3
48 pustulosis palmaris et plantaris 12.3
49 tranebjaerg svejgaard syndrome 12.1
50 psoriatic juvenile idiopathic arthritis 11.9

Graphical network of the top 20 diseases related to Psoriasis:

Diseases related to Psoriasis

Symptoms & Phenotypes for Psoriasis

UMLS symptoms related to Psoriasis:

pruritus, exanthema, psoriasiform rash

Drugs & Therapeutics for Psoriasis

PubMed Health treatment related to Psoriasis: 62

There are various treatment options for psoriasis: Basic therapy (skin care) : Care of the affected areas of skin using lipid -replenishing ointments, creams or lotions. This is done to keep the skin supple, protect it from injury and relieve itching . Some products also contain medications that are supposed to reduce shedding, such as urea or salicylic acid . Topical treatment : Products containing corticosteroids or vitamin D analogues are typically used in topical treatment (treatment applied to the skin from the outside). These are available in the form of creams, ointments lotions or foams. Light therapy : Light therapy, also known as phototherapy, involves exposing the plaques to ultraviolet light (UV light ). The UV light reduces inflammation in the skin , and also slows the production of cells . Sometimes medications called psoralens are used in combination with light therapy. Psoralens make the skin more sensitive to light. Light therapy is best suited for people who have moderate or severe psoriasis and in whom topical treatment alone wasn't effective enough. Medications that are taken orally or injected : These medicines are a treatment option for moderate or severe psoriasis. They inhibit the body's immune response. Methotrexate (MTX), fumaric acid esters, apremilast and biological drugs (biologics) are commonly used for this purpose. Basic moisturizing skin care is always recommended for psoriasis – during periods without any skin problems, too. There are also many herbal medicines for the treatment of psoriasis, including extracts of barberry (Mahonia aquifolium), birch bark or aloe vera. The effectiveness of these herbal medicines hasn't been tested in any good-quality studies, though. So it isn't known whether they can help. Some studies suggest that people with psoriasis who are overweight can improve the condition of their skin by losing a few pounds. It is sometimes claimed that a tonsillectomy (removal of the tonsils ) can relieve psoriasis symptoms , but there hasn't been much research in this area. Tonsillectomy usually isn't recommended because the operation may cause complications such as infections, bleeding and changes to the person's voice . There are also no studies showing that having your tonsils out can cure or prevent psoriasis.

Drugs for Psoriasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 440)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
Dapsone Approved, Investigational Phase 4 80-08-0 2955
Desoximetasone Approved Phase 4 382-67-2 5311067
Clobetasol Approved, Experimental, Investigational Phase 4 25122-41-2, 25122-46-7 32798 5311051
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
Clocortolone Approved Phase 4 4828-27-7, 34097-16-0 5282493 5311052
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
Sodium citrate Approved, Investigational Phase 4 68-04-2
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
carbamide peroxide Approved Phase 4 124-43-6
11 Strawberry Approved Phase 4
12 Orange Approved Phase 4
13 Artichoke Approved Phase 4
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
Abatacept Approved Phase 4 332348-12-6 10237
Zinc Approved, Investigational Phase 4 7440-66-6 32051
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
18 Ixekizumab Approved, Investigational Phase 4 1143503-69-8
19 Brodalumab Approved, Investigational Phase 4 1174395-19-7
Ustekinumab Approved, Investigational Phase 4 815610-63-0
Metformin Approved Phase 4 657-24-9 14219 4091
22 Vedolizumab Approved Phase 4 943609-66-3
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
Adalimumab Approved Phase 4 331731-18-1 16219006
Certolizumab pegol Approved Phase 4 428863-50-7
Tofacitinib Approved, Investigational Phase 4 477600-75-2
Mercaptopurine Approved Phase 4 50-44-2 667490
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
Capsaicin Approved Phase 4 404-86-4 1548943
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
36 retinol Phase 4
37 Retinol palmitate Phase 4
38 Tin Fluorides Phase 4
39 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
40 Immunoglobulin A Phase 4
41 Halobetasol Phase 4
Chondroitin Phase 4 9007-27-6 53477707
43 Clocortolone pivalate Phase 4
44 Olive Phase 4
45 Omega 3 Fatty Acid Phase 4
46 Chelating Agents Phase 4
47 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
48 Citrate Phase 4
49 diuretics Phase 4
50 Anticoagulants Phase 4

Interventional clinical trials:

(show top 50) (show all 1686)
# Name Status NCT ID Phase Drugs
1 Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study. Unknown status NCT02248792 Phase 4 Methotrexate
2 A Phase4,Multicenter, Randomized,Double-blind,Double Dummy, Parallel Controlled Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Treatment of Chinese Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01443338 Phase 4 Triptergium Wilfordii;Acitretin
3 A Phase 4 Multicenter, Randomized, Placebo-controlled Study Evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients With Moderate-to-severe Scalp Psoriasis Unknown status NCT03553433 Phase 4 Apremilast 30mg;Placebo Oral Tablet
4 The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
5 Proton Pump Inhibitors Use in Patients With Psoriasis Unknown status NCT02624544 Phase 4 esomeprazole;desonide
6 Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis Unknown status NCT00707070 Phase 4 efalizumab plus placebo;efalizumab plus acitretin
7 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
8 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
9 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use Unknown status NCT01132235 Phase 4
10 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
11 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
12 Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After Adalimumab Therapy Unknown status NCT01237262 Phase 4 Adalimumab, etanercept, infliximab
13 A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4 Ustekinumab;Placebo
14 Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness Unknown status NCT00150930 Phase 4
15 A Randomized Controlled Trial Comparing the Efficacy and Safety Profile of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis Unknown status NCT03408756 Phase 4 methotrexate
16 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
17 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
18 The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals Unknown status NCT01405352 Phase 4
19 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Treating Scalp Involvement in Subjects With Moderate to Severe Plaque Psoriasis Completed NCT00791765 Phase 4
20 Canadian Assessment of Patient Outcomes and Effectiveness of Enbrel (Etanercept) in Psoriasis Completed NCT00332332 Phase 4
21 A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects With Psoriasis Completed NCT00195507 Phase 4 Etanercept
22 A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4 Etanercept;Etanercept
23 Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05% Completed NCT01893567 Phase 4 Clobex Spray
24 A Multicenter, Open-label, Randomized, Pilot-study to Evaluate the Efficacy and Safety of the Combination of Etanercept (ETN) and Methotrexate and of Etanercept (ETN) Alone in Patients With Plaque Psoriasis Despite Methotrexate Therapy Completed NCT00161655 Phase 4 Etanercept;Methotrexate
25 A Randomized Pilot Study Evaluating the Efficacy and Safety of Etanercept in Patients With Moderate to Severe Plaque Psoriasis After Cessation of Ciclosporin Therapy Completed NCT00581555 Phase 4 Etanercept
26 Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate: a Phase IV, Multicenter, Randomized, Double-blind, Controlled Trial Completed NCT02313922 Phase 4 etanercept combined with methotrexate or etanercept combined with placebo
27 An Open-Label Phase 4 Study in Adult Patients With Chronic Plaque Psoriasis to Evaluate the Immune Response to Pneumococcal Vaccine in Subjects Treated With Alefacept Completed NCT00493324 Phase 4 alefacept;polyvalent pneumococcal vaccine
28 An Extension Study of Brodalumab in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma Completed NCT04183881 Phase 4 Brodalumab 210mg SC
29 Elocon vs Fluticasone in Localized Psoriasis Completed NCT00763529 Phase 4 Mometasone;Fluticasone
30 Evaluating Safety in Patients With Moderate to Severe Psoriasis Treated With Etanercept Completed NCT00581165 Phase 4 Etanercept
31 A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis Completed NCT03573323 Phase 4 Ixekizumab;Guselkumab;Placebo
32 Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population Completed NCT02533973 Phase 4 Xamiol® gel;Daivonex® scalp solution
33 Fase IV Clinical Trial to Evaluate Chondroitin Sulphate Efficacy and Safety in Patients With Knee Osteoarthritis and Psoriasis Completed NCT00669123 Phase 4 Chondroitin sulphate;Placebo
34 Safety and Efficacy of Etanercept in Patients With Moderate to Severe Plaque Psoriasis Who Have Shown an Unsatisfactory Response to Adalimumab or Infliximab Completed NCT00967538 Phase 4 etanercept 50 mg
35 A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris. Completed NCT02733874 Phase 4 Compound Clobetasol Propionate Ointment;Calcipotriol Betamethasone Ointment
36 A Randomised, Double-Blind, Active-Controlled, Parallel, Multi-Center Study to Investigate the Efficacy and Safety of Daivobet® Ointment in Patients With Psoriasis Vulgaris Completed NCT00248456 Phase 4 Calcipotriol plus betamethasone dipropionate ointment
37 An Open-Label, Multicenter Study of the Efficacy of Cloderm® Cream (Clocortolone Pivalate, 0.1%) in the Treatment of Moderate Plaque Psoriasis for 28 Days Completed NCT01714544 Phase 4 Cloderm Cream
38 A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Completed NCT00287118 Phase 4 Efalizumab
39 Efficacy and Safety of Alefacept in Combination With Narrow-band UVB (nbUVB) Compared to Alefacept Alone in Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed NCT00658606 Phase 4 alefacept
40 An Open-Label, Study Evaluating Topicort® Topical Spray 0.25% (Desoximetasone) in Patients With Scalp Psoriasis Completed NCT02985736 Phase 4 Topicort Topical Spray
41 A Study to Evaluate the Efficacy and Tolerability of Clobetasol Propionate vs. Vehicle in the Treatment of Mild to Moderate Plaque-Type Psoriasis Completed NCT00842153 Phase 4 Clobetasol propionate foam;Vehicle foam
42 An Open Label, Non-comparative, Multicentre, Phase IV Study to Evaluate the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis Completed NCT01373567 Phase 4 TINEFCON
43 A Single-Center, Open-Label Study to Assess Change in Psychosocial and Occupational Dimensions With Ustekinumab Treatment of Moderate-to-Severe Psoriasis Evaluated With the Psychological General Well Being (PGWB), Work Productivity and Activity Impairment (WPAI), Psoriasis Quality of Life-12 Items (PQOL-12), and Dermatology Life Quality Index (DLQI) Completed NCT01511315 Phase 4 Ustekinumab
44 A Study to Evaluate Safety and Efficacy of Clobetasol Propionate for Treatment of Plaque-Type Psoriasis in Adult Subjects. Completed NCT00852761 Phase 4 Olux-E Foam;Clobex lotion
45 Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast Completed NCT02749370 Phase 4 Etanercept
46 A Multicenter, Open-Label, Pilot Trial to Evaluate the Effectiveness and Safety of ENBREL(r) in Combination With Narrowband UVB Phototherapy for the Treatment of Psoriasis Completed NCT00110981 Phase 4 Etanerept;Etanercept
48 A Single-arm Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Subjects With Plaque Psoriasis Completed NCT02274792 Phase 4 Etanercept
49 An Evaluation of the Efficacy, Safety, Preference and Duration of Response of Clobex® (Clobetasol Propionate) Spray and Taclonex® (Calcipotriene 0.05%/Betamethasone Dipropionate 0.064%) Ointment in Subjects With Stable Plaque Psoriasis Completed NCT00437255 Phase 4 Clobetasol Propionate, 0.05%;Calcipotriene and betamethasone dipropionate ointment
50 A Comparison Between Clobetasol Propionate (Clobex®) Spray and Clobetasol Propionate (Olux®) Foam With Regard to Efficacy, Safety, Preference and Duration of Response in Stable Plaque Psoriasis Completed NCT00436540 Phase 4 Clobetasol Propionate 0.05% Spray;Clobetasol Propionate 0.05% Foam

Search NIH Clinical Center for Psoriasis

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Aloe vera preparation
Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
Coal Tar
Coal tar extract
Coal tar pitch volatiles
Cod Liver Oil
Colloid sulfur
Fish Liver Oils
Fluocinolone Acetonide
Methotrexate Sodium
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Salicylic Acid

Genetic Tests for Psoriasis

Genetic tests related to Psoriasis:

# Genetic test Affiliating Genes
1 Psoriasis 29

Anatomical Context for Psoriasis

MalaCards organs/tissues related to Psoriasis:

Skin, T Cells, Testes, Liver, Neutrophil, Endothelial, Bone

Publications for Psoriasis

Articles related to Psoriasis:

(show top 50) (show all 30346)
# Title Authors PMID Year
Research "recover from illness defense complex" helper T cell immune mechanisms based on the "Fuxie" theory clearing away heat evil thoroughly nourishing kidney treatment of recurrent blood-heat syndrome Psoriasis. 61 42
32443332 2020
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. 61 42
32427307 2020
MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? 46 61
17622355 2007
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial. 42
32386593 2020
Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis. 54 61
20506062 2010
Gene therapy for psoriasis in the K14-VEGF transgenic mouse model by topical transdermal delivery of interleukin-4 using ultradeformable cationic liposome. 54 61
20527041 2010
Enhanced expression and secretion of antimicrobial peptides in atopic dermatitis and after superficial skin injury. 54 61
20107483 2010
Injury downregulates the expression of the human cathelicidin protein hCAP18/LL-37 in atopic dermatitis. 54 61
19645825 2010
Regulation of the psoriatic chemokine CCL20 by E3 ligases Trim32 and Piasy in keratinocytes. 54 61
20054338 2010
[Etanercept and neoplasms]. 61 54
20492887 2010
Molecular dissection of psoriasis: integrating genetics and biology. 61 54
19812592 2010
Decrease in Mycobacterium tuberculosis specific immune responses in patients with untreated psoriasis living in a tuberculosis endemic area. 61 54
19609541 2010
Ustekinumab for the treatment of psoriasis: review of three multicenter clinical trials. 61 54
20502723 2010
Platelet activation in patients with psoriasis: increased plasma levels of platelet-derived microparticles and soluble P-selectin. 54 61
19962788 2010
The use of ustekinumab in autoimmune disease. 54 61
20218921 2010
Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions. 61 54
19517126 2010
Cellular and molecular effects of pulsed dye laser and local narrow-band UVB therapy in psoriasis. 61 54
20333742 2010
Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association. 61 54
20415816 2010
Molecular diagnostics of psoriasis, atopic dermatitis, allergic contact dermatitis and irritant contact dermatitis. 61 54
19818069 2010
[Production of interleukin-8 by circulating CLA+ T cells with skin tropism in patients with psoriasis and in healthy controls]. 61 54
20223157 2010
Sorafenib-associated remission of psoriasis in hypernephroma: case report. 54 61
20178713 2010
Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. 61 54
20112373 2010
Increased mast cell expression of PAR-2 in skin inflammatory diseases and release of IL-8 upon PAR-2 activation. 54 61
19889021 2010
Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease. 54 61
19879157 2010
Tumor necrosis factor-alpha-converting enzyme as a potential mediator of the influence of smoking on the response to treatment with narrowband ultraviolet B in psoriasis patients. 61 54
20070837 2010
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. 54 61
20050849 2010
Differential cytokine secretion of cultured bone marrow stromal cells from patients with psoriasis and healthy volunteers. 61 54
19889595 2010
Significance of the S100A4 protein in psoriasis. 54 61
19641515 2010
Cost-effectiveness analysis of TNF-alpha blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system. 54 61
20136921 2010
Unraveling the genetics of complex diseases: susceptibility genes for rheumatoid arthritis and psoriasis. 61 54
19446472 2009
Vasoactive intestinal peptide and inflammatory cytokines enhance vascular endothelial growth factor production from epidermal keratinocytes. 54 61
19785602 2009
Psoriasis patients generate increased serum levels of autoantibodies to tumor necrosis factor-alpha and interferon-alpha. 61 54
19800767 2009
Cell-wall-deficient bacteria: a major etiological factor for psoriasis? 54 61
20137493 2009
Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy. 61 54
20003607 2009
The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. 61 54
19830738 2009
Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments. 54 61
19681863 2009
AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. 61 54
19876791 2009
Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. 61 54
19895991 2009
Neuronal changes in psoriasis exacerbation. 61 54
19453808 2009
TNFalpha and its receptors in psoriatic skin, before and after treatment with etanercept. 61 54
20074459 2009
Ustekinumab: new drug. Suspicion of carcinogenicity: too great a risk for psoriasis patients. 61 54
19882785 2009
Proinflammatory cytokine production in HaCaT cells treated by eosin: implications for the topical treatment of psoriasis. 61 54
20074471 2009
Amelioration of psoriasis by anti-TNF-alpha RNAi in the xenograft transplantation model. 61 54
19568223 2009
Role of corticotropin-releasing hormone and receptor in the pathogenesis of psoriasis. 61 54
19560286 2009
Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. 54 61
19659473 2009
IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. 61 54
19648274 2009
Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. 54 61
19295614 2009
NGF and its receptor system: a new dimension in the pathogenesis of psoriasis and psoriatic arthritis. 54 61
19758188 2009
Using 'number needed to treat' to help conceptualize the magnitude of benefit and risk of tumour necrosis factor-alpha inhibitors for patients with severe psoriasis. 54 61
19438475 2009
Common polymorphisms in the interleukin-22 gene are not associated with chronic plaque psoriasis. 54 61
19469905 2009

Variations for Psoriasis

Copy number variations for Psoriasis from CNVD:

7 (show all 27)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 107130 17 1225928 31649829 Copy number CCL3L3 Psoriasis
2 107139 17 1225928 31649843 Copy number CCL3L1 Psoriasis
3 107160 17 1242109 31665953 Copy number CCL4L2 Psoriasis
4 110229 17 31562580 31665959 Copy number CCL4L1 Psoriasis
5 209406 6 2614953 31491069 Copy number MICA Psoriasis
6 211355 6 32593131 32665540 Copy number HLA-DRB5 Psoriasis
7 212281 6 3674895 32665540 Copy number HLA-DRB1 Psoriasis
8 212427 6 3795995 32719407 Copy number HLA-DQA1 Psoriasis
9 212447 6 3813334 32742444 Copy number HLA-DQB1 Psoriasis
10 230703 8 1 12700000 Copy number Psoriasis
11 241415 8 6200000 12700000 Copy number Psoriasis
12 241416 8 6200000 12700000 Copy number DEFB103 Psoriasis
13 241417 8 6200000 12700000 Copy number DEFB104 Psoriasis
14 241418 8 6200000 12700000 Copy number DEFB4 Psoriasis
15 241438 8 6200000 12700000 Gain DEFB103 Psoriasis
16 241439 8 6200000 12700000 Gain DEFB104 Psoriasis
17 241440 8 6200000 12700000 Gain DEFB105 Psoriasis
18 241441 8 6200000 12700000 Gain DEFB106 Psoriasis
19 241442 8 6200000 12700000 Gain DEFB107 Psoriasis
20 241443 8 6200000 12700000 Gain DEFB4 Psoriasis
21 241446 8 6200000 12700000 Gain SPAG11 Psoriasis
22 241447 8 6200000 12700000 High copy numbers Psoriasis
23 241468 8 6200000 12700000 Copy number DEFB4 Psoriasis
24 242595 8 7292685 7758729 Large repeat SPAG11 Psoriasis
25 242629 8 7327435 7723985 Large repeat DEFB106 Psoriasis
26 242645 8 7332652 7718770 Large repeat DEFB105 Psoriasis
27 242649 8 7340777 7710648 Large repeat DEFB107 Psoriasis

Expression for Psoriasis

LifeMap Discovery
Genes differentially expressed in tissues of Psoriasis patients vs. healthy controls: 35 (show all 41)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 S100A9 S100 calcium binding protein A9 Skin + 7.14 0.000
2 S100A7 S100 calcium binding protein A7 Skin + 7.06 0.000
3 S100A7A S100 calcium binding protein A7A Skin + 6.53 0.000
4 S100A8 S100 calcium binding protein A8 Skin + 6.48 0.000
5 SPRR2F small proline-rich protein 2F Skin + 6.27 0.000
6 PI3 peptidase inhibitor 3, skin-derived Skin + 6.19 0.000
7 KRT6C keratin 6C, type II Skin + 5.98 0.000
8 SPRR2A small proline-rich protein 2A Skin + 5.97 0.000
9 KRT6A keratin 6A, type II Skin + 5.90 0.000
10 SPRR2B small proline-rich protein 2B Skin + 5.41 0.000
11 KRT6B keratin 6B, type II Skin + 5.39 0.000
12 SPRR2D small proline-rich protein 2D Skin + 5.35 0.000
13 SERPINB3 serpin peptidase inhibitor, clade B (ovalbumin), member 3 Skin + 5.23 0.000
14 GJB2 gap junction protein, beta 2, 26kDa Skin + 4.97 0.000
15 SPRR2C small proline-rich protein 2C (pseudogene) Skin + 4.90 0.000
16 C10orf99 chromosome 10 open reading frame 99 Skin + 4.46 0.000
17 LCE3D late cornified envelope 3D Skin + 4.42 0.000
18 SPRR1A small proline-rich protein 1A Skin + 4.34 0.000
19 LCE3A late cornified envelope 3A Skin + 4.34 0.000
20 AKR1B10 aldo-keto reductase family 1, member B10 (aldose reductase) Skin + 4.33 0.000
21 SPRR1B small proline-rich protein 1B Skin + 4.29 0.000
22 KRT16 keratin 16, type I Skin + 4.27 0.000
23 KYNU kynureninase Skin + 4.26 0.000
24 LCN2 lipocalin 2 Skin + 4.20 0.000
25 SPRR2G small proline-rich protein 2G Skin + 4.12 0.000
26 LCE3E late cornified envelope 3E Skin + 4.12 0.000
27 SERPINB4 serpin peptidase inhibitor, clade B (ovalbumin), member 4 Skin + 3.97 0.000
28 FABP5 fatty acid binding protein 5 (psoriasis-associated) Skin + 3.89 0.000
29 IFI27 interferon, alpha-inducible protein 27 Skin + 3.80 0.000
30 TCN1 transcobalamin I (vitamin B12 binding protein, R binder family) Skin + 3.73 0.000
31 FABP5P2 fatty acid binding protein 5 pseudogene 2 Skin + 3.72 0.000
32 KLK6 kallikrein-related peptidase 6 Skin + 3.54 0.000
33 IL36G interleukin 36, gamma Skin + 3.50 0.000
34 DEFB103B defensin, beta 103B Skin + 3.46 0.000
35 PAMR1 peptidase domain containing associated with muscle regeneration 1 Skin - 3.43 0.000
36 GJB6 gap junction protein, beta 6, 30kDa Skin + 3.38 0.000
37 SPRR2E small proline-rich protein 2E Skin + 3.24 0.000
38 POSTN periostin, osteoblast specific factor Skin - 3.14 0.000
39 CD36 CD36 molecule (thrombospondin receptor) Skin + 3.12 0.000
40 IGFL1 IGF-like family member 1 Skin + 3.11 0.000
41 CACNA1H calcium channel, voltage-dependent, T type, alpha 1H subunit Skin - 3.11 0.000
Search GEO for disease gene expression data for Psoriasis.

Pathways for Psoriasis

Pathways related to Psoriasis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.66 MIR326 MIR31 MIR21 MIR203A MIR200A MIR17

GO Terms for Psoriasis

Biological processes related to Psoriasis according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of inflammatory response GO:0050728 9.65 MIR31 MIR146A MIR142
2 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.49 MIR21 MIR146A
3 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.46 MIR21 MIR17
4 cellular response to lipopolysaccharide GO:0071222 9.46 MIR21 MIR17 MIR146B MIR146A
5 negative regulation of interleukin-8 secretion GO:2000483 9.43 MIR203A MIR146A
6 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.4 MIR31 MIR146A
7 positive regulation of metalloendopeptidase activity GO:1904685 9.37 MIR21 MIR17
8 regulation of toll-like receptor signaling pathway GO:0034121 9.32 MIR146B MIR146A
9 gene silencing by miRNA GO:0035195 9.28 MIR326 MIR31 MIR21 MIR203A MIR200A MIR17
10 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.26 MIR21 MIR17
11 miRNA mediated inhibition of translation GO:0035278 9.26 MIR31 MIR21 MIR17 MIR146A

Molecular functions related to Psoriasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.23 MIR31 MIR21 MIR203A MIR200A MIR17 MIR146B

Sources for Psoriasis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....